Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Pfizer’s “Established” Pharma Business Expands to “Essential Health” to Include New Drugs, Copromoted Products
December 9, 2016
- Ethical Drug Sales Tumble 12.2% in October: Crecon Report
December 8, 2016
- Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
- Heike Prinz to Become 1st Female President of Bayer Yakuhin
December 7, 2016
- Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
- Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
- Kaketsuken Wraps Up Blanket Re-Inspection, Says There’s No Quality or Safety Concern
December 6, 2016
- GSK Won’t Invest in Aspen Japan
December 6, 2016
- Toyama Chemical Begins Japan PIII for Macrolide Antibiotic
December 6, 2016
- AZ Japan to Shed 40 Primary Care Jobs Via Voluntary Redundancy
December 6, 2016
- Novartis Files Tafinlar-Mekinist Combo for NSCLC
December 6, 2016
- Daiichi Sankyo’s HER2-Targeting ADC Gets Fast-Track Status in US
December 5, 2016
- Takeda, Lightstone Ventures Set Up Neuroscience R&D Firm
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Annual Price Revision Could Plunge Pharma Industry into Doldrums: Pfizer Japan Chief
December 5, 2016
- FDA Accepts sNDA for Abilify Maintena’s Bipolar I Disorder Indication
December 2, 2016
- Novartis Seeks Aplastic Anemia Indication for Revolade, Neoral
December 2, 2016
- Takeda to Build Dengue Vaccine Plant in Germany
December 2, 2016
- JACE for Giant Congenital Melanocytic Nevus Covered by Health Insurance: J-TEC
December 2, 2016
- Pfizer Japan Completes Transfer of Generics from Hospira Japan
December 2, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…